The city of hope experience with novel transplant regimens that incorporate standard and escalated dose 90YTTRIUM ibritumomab tiuxetan (90Y-Zevalin®) radioimmunotherapy (RIT) for autologous stem cell transplantation (ASCT) in patients with B-cell non-Hodgkin’s lymphoma (NHL): targeted intensification without increased toxicity and elimination of total body irradiation (TBI)
A. Nademanee, H. Fung, A. Molina, A. Krishnan, R. Rodriguez, L. Popplewell, R.T. Spielberger, M. O’Donnell, D. Snyder, P. Parker, A. Stein, N. Kogut, P. Falk, F. Sahebi, J. Zain, W. Saville, A. RaubitVolume:
10
Year:
2004
Language:
english
DOI:
10.1016/j.bbmt.2003.12.117
File:
PDF, 56 KB
english, 2004
File converter
More search results
More benefits 
